Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study

Calcified Tissue International

Volumn 64, Issue 2, 1999, Pages 93-99

  Brown, J P ^a   Hosking, D J ^b   Ste Marie, L G ^c   Johnston Jr , C C ^d   Reginster, J Y ^e   Ryan, W G ^f   Johnson, T D ^g   Bekker, P J ^g  

^a LAVAL UNIVERSITY   (Canada)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MONTREAL   (Canada)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Bisphosphonate; Paget's disease; Risedronate

Indexed keywords

RISEDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAGET BONE DISEASE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CALCIUM CHANNEL BLOCKERS; CONSUMER PRODUCT SAFETY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; TIME FACTORS;

EID: 0032965138     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900584     Document Type: Article

References (32)

1. Paget J (1877) On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans 60:37
2. Reddy SV, Singer FR, Roodman GD (1995) Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab 80:2108-2111
3. Mills BG, Frausto A, Singer FR, Ohsaki YU, Demulder A, Roodman GD (1994) Multinucleated cells formed in vitro from Paget's bone marrow express viral antigens. Bone 15: 443-448
4. Rebel A, Pouplard A, Filmon R, Basle M, Kouyoumdjian S, Lepatezour A (1980) Viral antigens in osteoclasts from Paget's disease of bone. Lancet 2:344-346
5. Kahn AJ (1990) The viral etiology of Paget's disease of bone: a new perspective. Calcif Tissue Int 47:127-129
6. Bataille R (1992) Etiology of Paget's disease of bone: a new perspective. Calcif Tissue Int 50:293-294
7. Singer FR (1990) Paget's disease of bone. In: Hazzard WR, Endres R, Bierman EL, Blass JP (eds) Principles of geriatric medicine and gerontology, 2nd ed. McGraw-Hill, New York, pp 843-848
8. Khairi MRA, Altman RD, DeRosa GP, Zimmerman J, Schenk RK, Johnston CC (1977) Sodium etidronate in the treatment of Paget's disease of bone. Ann Intern Med 87:656-663
9. Siris ES, Canfield RE, Jacobs TP, Baquiran DC (1980) Long-term therapy of Paget's disease of bone with EHDP. Arthritis Rheum 23:1177-1184
10. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ (1994) Bisphosphonates: structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA (eds) Bone and mineral research. Elsevier Science, New York, pp 265-306
11. Bekker P, Licata A, Harris S, Genant H, Charles P, Johnston C, Jr (1996) Risedronate dose response in prevention of early postmenopausal bone loss (abstract). J Bone Miner Res 11 (suppl 1):M658
12. Delmas PD, Chapuy MC, Edouard C, Meunier PJ (1987) Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 83(2):276-282
13. Johnston CC, Jr, Khairi MRA, Meunier PJ (1980) Use of etidronate (EHDP) in Paget's disease of bone. Arthritis Rheum 23:1172-1176
14. Chines A, Bekker P, Clarke P, Hosking D (1996) Reduction of bone pain and alkaline phosphatase in patients with severe Paget's disease of bone following treatment with risedronate (abstract). J Bone Miner Res 11 (suppl 1):M760
15. Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ (1987) Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 217:79-98
16. Patel S, Stone MD, Coupland C, Hosking DJ (1993) Determinants of remission of Paget's disease of bone. J Bone Miner Res 8:1467-1473
17. Mitchell DY, Eusebio RA, Heise MA, Pallone KA, Clay ME, Russell DA, Melson CW (1996) The effect of dosing regimen on the pharmacokinetics of risedronate administered to healthy subjects. J Bone Miner Res 11 (suppl 1):M661
18. Delmas PD, Chapuy MC, Vignon E, Charhon S, Briancon D, Alexandre C, Edouard C, Meunier PJ (1982) Long-term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab 54:837-844
19. 12MDP) on Paget's disease of bone. Adv Exp Med Biol 128:299-309
20. Frijlink WB, Bijvoet OLM, Te Velde J, Heynen G (1979) Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:799-803
21. Fraser TR, Ibbertson HK, Holdaway IM, Rutland M, King A, Dodd G, Wattie DJ (1984) Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate): a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate). Aust N Z J Med 14:811-818
22. Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Deroisy R, Lecart MP, Fontaine MA, Collette J, Franchimont P (1988) Biological and clinical assessment of a new bisphosphonate (chloro-4-phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone. Bone 9:349-354
23. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot C, Titeux L, Reginster JY, Dougados M (1995) Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38:851-858
24. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M (1996) Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81:961-967
25. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1020
26. Castell DO (1996) "Pill esophagitis" - the case of alendronate. N Engl J Med 335:1058-1059
27. Sorrentino D, Trevisi A, Bernardis V, DeBiase F, Labombarda A, Bartoli E (1996) Esophageal ulceration due to alendronate. Endoscopy 28:529
28. Naylor G, Davies MH (1996) Oesophageal stricture with alendronic acid. Lancet 348:1030-1031
29. Maconi G, Bianchi Porro G (1995) Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 90:1889
30. Abdelmalek MF, Douglas DD (1996) Alendronate-induced ulcerative esophagitis. Am J Gastroenterol 91:1282-1283
31. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, O'Fallon WM, Riggs BL (1994) Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320-322
32. Kanis JA, McCloskey EV, O'Doherty D, Hamdy NAT, Bickerstaff D (1991) Treatment of Paget's disease with the new bisphosphonates. In: Singer FR, Wallach S (eds) Paget's disease of bone: clinical assessment, present and future therapy. Elsevier, New York, pp 112-134